ANTENGENE-B (06996) plans to conduct share buybacks in the market.
Tak Chi Pharmaceutical-B (06996) announced that they plan to exercise their relevant powers in accordance with the general authorization granted by the company's shareholders at the annual general meeting held on June 10, 2026, to repurchase up to 67,924,000 shares of the company, which is 10% of the total number of issued shares as of the date of the annual general meeting (excluding any treasury shares).
ANTENGENE-B (06996) announced that it plans to exercise its general authorization granted by the company's shareholders at the annual general meeting held on June 10, 2026, to repurchase up to 679.244 million shares of the company's shares, representing 10% of the total number of issued shares (excluding any treasury shares) as of the date of the annual general meeting.
On June 24, 2026, the Board of Directors has resolved to utilize the share repurchase authorization and to repurchase shares on the open market at a maximum total cost of HK$50 million, based on prevailing market conditions. The Board of Directors may subsequently cancel the repurchased shares or hold them as treasury shares, depending on the market conditions at the time and the capital management needs of the group.
The company will fund the proposed share repurchase with its internal resources. The proposed share repurchase demonstrates the company's confidence in its business prospects and outlook, and is expected to ultimately benefit the company and create value for shareholders. The Board of Directors believes that the company's current financial resources will enable it to implement the proposed share repurchase while maintaining a strong financial position. The Board of Directors considers the proposed share repurchase to be in the best interests of the company and its shareholders overall.
Related Articles

Brokerage morning meeting highlights | Brand focus on high-performance certainty targets creating attention on marginal improvement opportunities

C HEALTH GP(08225): It is recommended to adopt the new equity purchase plan.

HUTCHMED (00013) will release key phase II trial data on fruquintinib for the treatment of intrahepatic cholangiocarcinoma at the 2026 European Society for Medical Oncology Congress on Gastrointestinal Oncology.
Brokerage morning meeting highlights | Brand focus on high-performance certainty targets creating attention on marginal improvement opportunities

C HEALTH GP(08225): It is recommended to adopt the new equity purchase plan.

HUTCHMED (00013) will release key phase II trial data on fruquintinib for the treatment of intrahepatic cholangiocarcinoma at the 2026 European Society for Medical Oncology Congress on Gastrointestinal Oncology.

RECOMMEND





